{"id":5095,"date":"2014-11-06T11:11:52","date_gmt":"2014-11-06T11:11:52","guid":{"rendered":"\/?p=5095"},"modified":"2014-11-06T11:39:58","modified_gmt":"2014-11-06T11:39:58","slug":"investors-cant-wait-to-see-praxsyn-corp-otcmktspxyns-q3-report","status":"publish","type":"post","link":"\/articles\/investors-cant-wait-to-see-praxsyn-corp-otcmktspxyns-q3-report\/","title":{"rendered":"Investors Can’t Wait to See Praxsyn Corp (OTCMKTS:PXYN)’s Q3 Report"},"content":{"rendered":"\n

Not that long ago, the company that we now know as Praxsyn Corp (OTCMKTS:PXYN<\/a>) was called PAWS Pet Company, Inc and once you take a look at the SEC filings, you’ll see that it wasn’t doing particularly well. At the end of the third quarter of last year, for example, they had just over $8 thousand in the bank, current liabilities of around $3.5 million, no revenue since inception, and a quarterly operating loss of about $440 thousand. The previous business plan was never going to work so at the beginning of 2014, they effectuated a reverse merger and acquired Mesa Pharmacy, LLC<\/strong>, a former subsidiary of a company called Pharmacy Development Corp.<\/strong> Now, things are quite a bit different.<\/p>\n

During Q2 of 2014, for example, PXYN<\/a><\/strong> managed to log a whopping $23.2 million in sales<\/strong> and a gross profit of over $22 million<\/strong>. Without a shadow of a doubt, these are some impressive figures, especially when it comes to OTC companies, but the growth that PXYN<\/a><\/strong>‘s revenues have experienced is even more astonishing. The sales registered during the corresponding quarter of 2013 amounted to less than $500 thousand which represents a mind-bending 4,560% leap year over year<\/strong>. <\/p>\n

All in all, when it comes to revenues, the company is definitely growing. Unfortunately, the same can’t be said about the stock.<\/p>\n

The new ticker became effective two months ago, but instead of giving PXYN<\/a><\/strong> a push, it put quite a lot of pressure on it. Between September 5 and October 9, the stock lost more than a third of its value and dropped from just under $0.055 to less than $0.035. Now, though, it seems to be more determined than ever to climb to some more respectable levels. After five consecutive green sessions and a 20% jump yesterday, it’s sitting at just under $0.08. The reason?<\/p>\n

The 10-Q covering the third quarter of 2014 should be out within the next ten days and judging by the hype and excitement around message boards, many people expect to see a positive bottom line in it. Despite the wobbly stock performance, they appear to be convinced that once profitability is reached, PXYN<\/a><\/strong> will become one of the more stable tickers on the OTC Markets.<\/p>\n

Hopefully, this will be the case and hopefully, a positive bottom line is indeed within reach because, while the sales figures are impressive, the rest of PXYN<\/a><\/strong>‘s Q2 report is far from confidence-inspiring. Here’s a quick rundown of the most important financials:<\/p>\n